A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Effect of 150 microg Aleglitazar Once Daily in Healthy Subjects Treated With 325 mg Aspirin Once Daily on Renal Function, Renin-angiotensin System and Platelet Aggregation

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Effect of 150 microg Aleglitazar Once Daily in Healthy Subjects Treated With 325 mg Aspirin Once Daily on Renal Function, Renin-angiotensin System and Platelet Aggregation

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Aleglitazar (Primary) ; Aspirin
  • Indications Cardiovascular disorders; Thrombosis; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Roche
  • Most Recent Events

    • 27 Mar 2012 Results presented at the 61st Annual Scientific Session of the American College of Cardiology.
    • 19 Sep 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
    • 19 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top